VCNX
VCNX clinical trials: VACCINEX, INC.
Every trial on ClinicalTrials.gov where VACCINEX, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 7
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
VCNX on the catalyst calendar · VCNX registry changes
- Primary completion Dec 31, 2028Sponsor estimatePhase 1/Phase 2NCT05102721Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic AdenocarcinomaVaccinex Inc. · Metastatic Pancreatic AdenocarcinomaActive, not recruitingVCNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 24, 2024ActualPhase 1/Phase 2NCT04815720Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckVaccinex Inc. · Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)CompletedVCNXLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 5, 2024ActualPhase 1/Phase 2NCT04381468SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)Vaccinex Inc. · Alzheimer DiseaseCompletedVCNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 9, 2020ActualPhase 1/Phase 2NCT03268057VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung CancerVaccinex Inc. · Carcinoma, Non-Small-Cell LungCompletedVCNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2020ActualPhase 2NCT02481674A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of PepiVaccinex Inc. · Huntington's DiseaseCompletedVCNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2014ActualPhase 1NCT01764737Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MSVaccinex Inc. · Multiple SclerosisCompletedVCNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2014ActualPhase 1NCT01313065Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid TumorsVaccinex Inc. · Solid TumorsCompletedVCNXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 17, 2026ActualPhase 1NCT05378464Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast CancerH. Lee Moffitt Cancer Center and Research Institute · HER2-positive Breast CancerSuspendedVCNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 9, 2027Sponsor estimatePhase 1NCT03690986VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerEmory University · Squamous Cell Carcinoma of the Head and NeckActive, not recruitingVCNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2023ActualPhase 1NCT03769155VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaEmory University · Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Active, not recruitingVCNXCollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 28, 2021ActualPhase 1NCT03373188VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerEmory University · Colon Carcinoma Metastatic in the LiverCompletedVCNXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 4, 2021ActualPhase 1NCT03425461Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaJonsson Comprehensive Cancer Center · Metastatic MelanomaTerminatedVCNXCollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner